The present invention is directed to a method and system for treatment utilizing energy such as ultrasound energy. Specifically, the present invention is directed at treating tissues at various locations with ultrasound energy wherein the ultrasound energy is applied at different levels at different locations within the tissue.
Energy, such as ultrasound energy, can be applied to treat tissue or perform traditionally invasive procedures in a non-invasive manner. The application of ultrasound energy provides both thermal and/or mechanical effects that help treat certain ailments such as acne and enable many traditional invasive procedures to be performed non-invasively.
Current ultrasound devices provide energy to tissue within a region of interest. The energy is emitted from an ultrasound system and travels a certain depth within the tissue and has an effect on the tissue. The effect can be ablative, coagulative, non-ablative, or non-coagulative and is generally caused by the thermal and/or mechanical properties that ultrasound has on tissue. Thermal properties increase the temperature of the tissue at the region of interest while the mechanical effects are achieved by cavitation, streaming, radiation force, and other natural mechanical effects of ultrasound.
Further, ultrasound energy has certain spatial and temporal properties when it is applied to the region of interest. The “temporal” properties refer to the time that the ultrasound energy is applied while the “spatial” properties refer to the space within the tissue that is affected by the ultrasound energy at a specific moment in time.
While effective, existing ultrasound devices only affect a specific portion of the tissue at a certain depth within the region of interest based upon the configuration of the ultrasound device. For example, an ultrasound device might be configured to affect an area five millimeters below the surface of the skin. The tissue from the surface of the skin to the depth of five millimeters is spared and not treated by the ultrasound energy. Sparing these intervening spaces of tissue hinders the overall beneficial effect of ultrasound as treatment of this intervening tissue increases ultrasound treatment's overall efficacy.
Therefore, it would be beneficial to provide an ultrasound device and treatment method that treats multiple areas of tissue in a region of interest including intervening tissue and even the distal layer of tissue. It would also be advantageous to provide a system and method that treated numerous depths of tissue by varying the spatial and temporal effects of ultrasound at different depths such has having ablative or coagulative ultrasound applied to certain depths of tissue while non-ablative ultrasound is applied to other depths of tissue.
A method and system for creating a combined energy profile by providing energy to tissue at different locations within a region of interest is provided. In an exemplary embodiment, the energy is ultrasound energy and it is provided at various locations and/or depths to conduct traditionally invasive procedures non-invasively by utilizing the thermal and/or mechanical effects of ultrasound energy. In certain exemplary embodiments, ultrasound energy with different spatial and temporal characteristics is applied to a region of interest (“ROI”) to treat the ROI.
An exemplary system and method that provides ultrasound energy with different spatial characteristics creates different effects at different locations and/or depths within the tissue being treated. For example, ultrasound energy may be applied with a larger geometric shape at one depth and a smaller geometric shape at another depth without sparing the intervening tissue from the skin's surface to the deepest depth of ultrasound penetration. In certain exemplary embodiments, the application of ultrasound energy with differing spatial characteristics can increase the overall temperature at the ROI with less energy use.
Further, the time that the ultrasound energy is applied can also change the effects of the ultrasound energy at different tissue locations or depths. In one exemplary embodiment, energy can be applied at longer times at certain depths and shorter times at other depths without sparing intervening tissue. These temporal changes in the application of ultrasound energy can affect the results of the ultrasound treatment at the ROI.
In certain exemplary embodiments, both the temporal and spatial characteristics of ultrasound energy effect the overall treatment provided. In yet other embodiments, only the temporal changes effect the treatment. Still in yet other embodiments, only the spatial characteristics effect the treatment.
Various different ultrasound systems configured to provide the combined energy profile fall within the scope of the present invention. In one exemplary embodiment, an ultrasound system with a transducer probe comprising different transduction elements is provided. Each transduction element is capable of producing ultrasound energy for different time lengths and with a different geometric pattern.
Applying ultrasound energy at different spatial and temporal levels increases the temperature and/or utilizes the mechanical effects of ultrasound energy throughout the entire ROI from the surface of the skin to the deepest location of ultrasound energy penetration without sparing intervening tissue. Treating a ROI with a combined energy profile can be highly effective at treating certain ailments.
For example, acne at a ROI can affect multiple depths of tissue and acne can be treated at the top of the tissue where pimples form by applying ablative ultrasound energy to the top portion of the tissue. The various subcutaneous tissues below the surface of the skin can also be treated with non-ablative ultrasound energy to treat individual pilosebaceous glands that cause the acne.
The subject matter of the invention is particularly pointed out in the concluding portion of the specification. The invention, however, both as to organization and method of operation, may be best understood by reference to the following description taken in conjunction with the accompanying drawing figures, in which like parts may be referred to by like numerals.
The present disclosure may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions. For example, certain embodiments may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions and be capable of emitting ultrasound energy for imaging or treatment or combinations thereof.
With reference to
With particular reference to
Further, ROI 12 can include multiple layers or types of tissue such as, but certainly not limited to, skin, fat, muscles, tendons, cartilage, ligaments, the superficial muscular aponeurotic system, other fibrous or connective tissues, the dermis, epidermis, organ tissues, mucous membrane, hair bulb, hair shaft, hair follicle between the hair bulb, apocrine sweat glands, eccrine glands lying within the dermis, fat or muscle, tumors, and/or any other tissue of interest.
Further, ROI 12 can be limited to specific depths such as 0-20 millimeters or it can deeper into the body. In one exemplary embodiment, ROI 12 is at a depth in the range of 0.2 to 8 millimeters while in another exemplary embodiment, ROI 12 is at a depth of 0.3 to 6 millimeters.
Alternatively, ROI 12 can be limited to the surface of the skin or immediately below the surface, or areas between the surface and greater depths within the body. While only one ROI 12 is depicted, a plurality of ROIs 12 can be treated by the system in an exemplary embodiment. Also, other glands can be treated by the method and system of the present invention. These glands comprise sweat glands, endocrine glands, and other glands. Therefore, the method and system of the present invention can be used to treat acne, oily skin and hair, as well as other ailments. ROI 12 may also consist of one more organs, such as skin, or a combination of tissues either superficial or deep within the body.
In an exemplary embodiment, energy such as ultrasound energy 16 is emitted from system 10 at multiple depths throughout ROI 12 to target numerous depths of tissue within a specific ROI 12. In addition to ultrasound energy 16, other energy forms such as photon-based energy such as laser energy, radio frequency energy (certain examples of radio frequency include monopolar and bipolar radio-frequency current), mechanical energy such as massage or other vibration-based energy and other energies can be used and fall within the scope of the present invention. Further, various light energy can be used in connection with ultrasound energy 16 to treat ROI 12. Certain exemplary frequencies of light are in the range of 400 nm to various wavelengths for infra-red light can be used.
For example, blue light at a wavelength of approximately 400 to 450 nm can be used to pre-treat ROI 12 before the application of ultrasound energy 16 or blue light of this wavelength can be used with ultrasound to increase the efficacy of treatment. In another embodiment, visible light in the range of 600 to 1350 nm can be used with the ultrasound during treatment.
Multiple depths of tissue within ROI 12 are treated from the surface down to the deepest point of ultrasound energy penetration and no intervening tissue is spared in one embodiment of the present invention. For example, ultrasound energy 16 from one source may have a spatial characteristic of affecting an area 15 millimeters in diameter 5 millimeters below the surface of the skin while ultrasound energy from another source may affect an area 9 millimeters below the surface of the skin with an area of 30 millimeters in diameter.
Various different time frames for ultrasound energy 16 emissions can be used in the present invention. Certain exemplary time frames include ranges of approximately fifty microseconds to fifteen minutes. Another exemplary time range is five hundred milliseconds to sixty seconds and yet another exemplary time frame is one second to sixty seconds. Numerous other time frame ranges can be implemented depending on the particular treatment application desired.
Moreover, the temporal characteristics of ultrasound energy 16 affecting ROI 12 can be changed for each location within the total area that comprises ROI 12. For example, ultrasound energy 16 that is directed 5 millimeters below the surface of the skin may only be emitted for 10 seconds while ultrasound energy 16 that is directed 9 millimeters below the surface of the skin may be emitted for 20 seconds. In other exemplary embodiments, these temporal properties of ultrasound energy 16 can be changed so that ultrasound energy 16 is pulsed for a certain duration. The time duration of each pulse of ultrasound energy can be changed as well. For example, ultrasound energy 16 can be emitted in 20 one second pulses at a depth of 5 millimeters below the surface of the skin and at 10 four second pulses at a depth of 10 millimeters below the surface of the skin. The different spatial and temporal properties of ultrasound energy 16 can be changed for each location and/or depth within a total ROI 12 to create a combined temperature profile.
As depicted in
There are numerous possible medical applications for the system and method of the present invention. Many treatments effectuated by the method and system of the present invention result from increased blood perfusion at ROI 12 and the associated benefits of increased perfusion. For example, the application of ultrasound energy 16 at a specific location within ROI 12 can result in localized perfusion.
The increased perfusion can assist and/or stimulate numerous effects such as epidermal stimulation and a processes known as “colleganesis” or increasing the amount of collagen at ROI 12. Increasing perfusion also brings more of the body's natural repair cells (as discussed herein) to ROI 12 and that can assist with cell regeneration as well as other cellular repair processes and fibroblast activity. Increasing perfusion at ROI 12 also increases epidermal thickness and dermal mass. Other benefits from increasing blood perfusion are better skin tone and texture.
The application of ultrasound energy 16 also decreases certain conditions or ailments. For example, applying ultrasound energy 16 decreases pore size and blemishes (whether the blemishes are associated with acne or not). Other ailments or conditions that can be decreased by the application of ultrasound energy include, but are certainly not limited to, vascular defects, superficial wrinkles, uneven complexion, dischromia/blotchiness, and certain gland activity (such as the sebaceous gland).
The application of ultrasound energy 16 at higher levels powerful enough to cause ablation or coagulation at the skin surface or at greater depths within ROI 12 produces other effects. These effects can comprise the removal of warts, scars, moles, corns, calvi or calluses from ROI 12. Shaving bumps or “pseudofolliculitis barbae” can be treated or prevented with the method and system of the present invention. In this regard, the bumps can be ablated from the human body by applying ultrasound energy 16 at ablative levels or the bumps can be treated or prevented by applying ultrasound energy 16 at deeper depths at non-ablative levels to increase perfusion to the area with shaving bumps to treat the cause of the shaving bumps such as infected glands. Moreover, the application of ultrasound energy 16 at ROI 12 can create lesion by heating or burning tissue, and/or cavitation within ROI 12.
In the examples set forth above, while certain tissues are being removed from ROI 12 by applying ultrasound energy 16 at ablative levels, ultrasound energy 16 at lower, non-ablative levels can be applied deeper within ROI 12. For example, ultrasound energy 16 can be applied at ablative or coagulative levels to remove a mole from the surface of the skin while lower, non-ablative and non-coagulative ultrasound energy can be applied at deeper depths to increase blood perfusion at those depths. Changing the temporal and spatial parameters of the application of ultrasound energy 16 at different locations determines whether or not it is applied at an ablative or non-ablative level.
Various other effects resulting from the application of ultrasound energy 16 at ROI 12 comprise peaking out inflammation or edema at ROI 12. Further, increased angiogenesis (the growth of blood vessels) can result by the application can result from applying ultrasound energy 16 to ROI 12.
As described herein, applying ultrasound energy 16 at ROI 12 can have curative and non-curative effects. Further, while numerous examples of treatments have been described herein, other treatments can be effectuated and fall within the scope of the present invention. Further, in one exemplary embodiment, two or more types of treatment can occur simultaneously at ROI 12. For example, a mole can be burned off at the skin's surface while increased angiogenesis occurs at a deeper level within the tissue at ROI 12.
In an exemplary embodiment, the spatial and temporal properties of ultrasound energy 16 can be changed to effectively treat acne and the associated pilosebaceous unit 14. Specifically, ultrasound energy 16 can be applied with spatial and temporal properties that result in ablation of tissue at the surface of the skin by raising the temperature at the skin's surface above 60° C. for approximately one second, which causes ablation, or above any time-temperature threshold. According to one exemplary embodiment, ultrasound energy 16 is applied at non-ablative levels below the surface in ROI 12 near pilosebaceous unit 14. Ultrasound energy is applied at non-ablative levels by varying the spatial and temporal characteristics of ultrasound energy 16 to levels where they do not raise the temperature above ablative levels or 60° C.
Further, with reference to
In another exemplary embodiment, ultrasound energy 16 is applied at different depths or locations within ROI 12 non-simultaneously. In this exemplary embodiment of non-simultaneous ultrasound energy 16 emissions, ultrasound energy 16 from one source can be applied to raise the temperature at certain predetermined depth to a certain level. Ultrasound energy from another source aimed to target an area within ROI 12 above the first area targeted by the first source. Because the first area in ROI 12 is already heated and adjacent to the second area, the second area is in effect pre-heated and less ultrasound energy 16 is required to heat the second area. By utilizing ultrasound energy 16 from two sources and applying it in this stepped form, less overall energy is needed than if energy was used from a single source.
In this example, ultrasound energy 16′ is applied for a longer time period near the skin and epidermis while ultrasound energy 16 is applied for a short time period in the subcutaneous fat of ROI 12. The temporal characteristics of ultrasound energy 16 can be changed in other exemplary embodiments of the present invention depending on the treatment desired.
With reference now to
The application of different levels of ultrasound energy 16 at different depths of tissue creates a combined therapy profile at ROI 12. For instance, instead of merely treating acne by targeting pilosebaceous unit 14 and surrounding area with energy at ablative or non-ablative levels (as described in co-pending U.S. patent application Ser. Nos. 11/163,177 and 11/738,682 entitled Method For Treating Acne and Sebaceous Glands and Method and System for Non-Ablative Acne Treatment and Prevention respectively wherein both such applications are herein incorporated by reference in their entirety) to destroy or otherwise effect pilosebaceous unit 14 and its contents, all of the tissue at ROI 12 can be targeted to treat and prevent acne or other ailments.
For example, pilosebaceous unit 14 can be treated with ablative levels to destroy it and prevent unwanted sebum production. With the pilosebaceous gland destroyed or otherwise inhibited, sebum production is halted and future acne is prevented from developing. But, scarring, scars, blackheads, whiteheads, cysts, and scarring may still be present at the top layers of the skin such as the dermis. These layers of tissue can be treated by the application of ultrasound energy 16 at lower, non-ablative, and non-coagulative levels than what is applied at the depth of pilosebaceous unit 12.
Applying ultrasound energy 16 at lower levels at the surface of the skin heats the surface. The body's natural reaction to this increased temperature at ROI 12 is to increase blood perfusion to the ROI 12. The increased blood perfusion delivers more blood to ROI 12. The increased blood at ROI 12 results in increased number of repair cells contained within the blood to be delivered to ROI 12. Specifically, the more blood that flows to ROI 12, the more fibroblast cells and other therapeutic leucocyte cells (white blood cells) such as lymphocytes, macrophages, and neutrophils are at ROI 12 to treat current acne and prevent future acne from developing. The repair cells treat existing acne by helping acne lesions heal faster. Future acne is prevented because more nutrients at ROI 12 are able to fight acne-causing bacteria such as P-acnes.
Therefore, in this example, acne is treated by targeting multiple tissue depths at ROI 12. The depth within ROI where pilosebaceous unit 14 is located is treated with ultrasound energy 16 at one level to cease sebum production to prevent future acne from developing. Moreover, the layer where the effects of acne are seen (at the skin) is also treated with ultrasound energy 16 to help heal the scars and visible effects of acne.
In another exemplary embodiment, the temperature range within the depths of tissue can be reversed. In this exemplary embodiment, energy such as ultrasound energy 16 is applied at ablative or coagulative levels at the surface of the skin and at lower, non-ablative and non-coagulative levels at deeper depths. In this exemplary embodiment, a mole or cyst can be “burned” off of the skin at the ROI while the application of energy at deeper depths can cause increased blood perfusion which heals the area once the mole or cyst is removed and/or treated.
Applying energy such as ultrasound energy 16 at multiple depths and at different levels simultaneously treats all the tissue at the ROI 12 with the thermal and/or mechanical effects of ultrasound. The thermal effects raise the temperature above the body's normal temperature. These temperature ranges can be in whatever range needed to affect a particular result. According to the present invention, a certain amount of ultrasound energy 16 can be applied at a pre-determined depth to raise the temperature at that depth to achieve a certain result. Certain zones with a given temperature can be created at various levels of tissue depending on the level of energy provided.
For example, it might be necessary to raise the temperature to fifty degrees or more at the surface and dermal layer of tissue to burn off a mole, tumor, or other piece of unwanted skin or tissue. During this application of ultrasound energy 16, it may also be desirable to raise the temperature at a deeper depth much lower, to only five or ten degrees above the body's normal temperature to achieve a result such as increased blood perfusion. The lower temperature at one zone or layer within the tissue and higher temperature at another zone treats the entire ROI 12.
Besides temporal changes at various depths within the tissue, ultrasound energy 16 also has certain mechanical effects that can be used for treatment. In an exemplary embodiment, these mechanical effects comprise cavitation, streaming, radiation force, oscillatory forces, and sheer stress on cellular membranes of cells that comprise tissue that is being targeted. These mechanical effects such as cavitation and streaming create various forces that contact cellular walls. For example, when using the method and system of the present invention to treat acne, ultrasound energy can be used to contact the cellular walls of P-acnes and other acne causing organisms which damage or kill them. Further, these mechanical effects can also help drive medicinal creams and other agents into tissue cells to better effectuate treatment and assist in transdermal drug delivery for acne or other forms of treatment.
Just as the case with thermal effects, these mechanical effects may be provided at certain depths and zones within ROI 12. Applying energy at a certain level at a certain depth is used to cause certain mechanical effects at that level. In an exemplary embodiment, the more ultrasound energy 16 applied, the more mechanical effects are realized. Lower energy results in fewer effects. For example, applying energy at greater levels at certain locations within the tissues will result in greater mechanical effects such as streaming and cavitation which may be needed at those locations to achieve a certain result.
The amount of energy can vary at different levels and cause specific effects at one level while causing another effect at another level simultaneously. This treatment at different levels can create a combined treatment that works with or independently of the thermal effects described above. For example, providing ultrasound energy 16 at higher levels may be needed to cause sufficient cavitation and/or streaming at the depth of tissue where a pilosebaceous unit 14 is located and may be necessary to destroy bacteria within the pilosebaceous unit to prevent and cure acne.
As ultrasound energy 16 is being applied at sufficient levels to cause cavitation and/or streaming sufficient to destroy bacteria, lower energy levels could be applied at other area within ROI 12. Applying ultrasound energy 16 at lower levels at other depths and locations within ROI 12 may be needed to achieve other effects such as transdermal drug delivery. Transdermal drug delivery is achieved by using the mechanical effects to push medicines and other medicants into the tissue cells at ROI 12. Further, in an exemplary embodiment, the medicines can be contained within a coupling gel, cream, or other substance that is used to couple probe 26 or transducer to the patient's body at ROI 12.
An exemplary system 10 for a combined therapy profile treatment is provided and depicted in
An exemplary probe 26 is a transducer that emits ultrasound energy into ROI 12 to heat ROI 12 at specific depths and/or cause certain mechanical effects at specific depths. A coupling agent is used to couple probe 26 to a patient's body in one exemplary embodiment. In another exemplary embodiment, suction is used to attach probe 26 to the patient's body.
With additional reference to
The elements within the rings may be capable of emitting energy reaching 15 mm, 20 mm, and 25 mm below the skin's surface respectively in this exemplary embodiment. In order to reach a certain depth within ROI 12, each transduction element 50 is constructed so that it may emit ultrasound energy 16 to reach this depth. System 10 can emit ultrasound energy at various frequency ranges. Certain exemplary ranges include about 0.10 MHz to 100 MHz or more. More specifically, exemplary frequencies include about 0.15 MHz and 0.2 MHz as lower frequencies and about 0.15 MHz to 100 MHz or more as higher frequencies. For example, in order to reach a depth of 0-15 mm, transduction element 50 has an operating power of about 10-100 watts and emits ultrasound energy 16 at a frequency of about 1-12 MHz. In order to reach a depth of about 0-20 mm, transduction element 50 has an operating power of about 20-200 watts and emits ultrasound energy at a frequency of about 1-9 MHz. Finally, to achieve a depth of about 0-25 mm, transduction element 50 has an operating power of about 1-120 watts and emits ultrasound energy 16 at a frequency of about 1-20 MHz.
With reference to
Energy such as ultrasound energy 16 can be emitted at various levels from each transduction element. These levels can be changed by varying the amount of energy emitted or the time it is emitted from system 10. For example, ultrasound energy 16 can be emitted at ablative or coagulative levels by being emitted at a high power for a short time or low power for a longer duration. The energy emission and time frames can be varied to achieve the desired level of energy emission. Moreover, the penetration depth of ultrasound energy 16 may be changed depending on which ring 46-48 it is emitted from. For example, as shown in
In one exemplary embodiment, transduction elements 50 are configured to emit ultrasound energy at a focal depth of 3-4 millimeters. In other exemplary embodiments, a single transducer or probe with multiple elements 50 is configured to produce variable amounts of ultrasound energy. Specifically, a transducer can contain numerous elements 50 and each element 50 is constructed to emit ultrasound energy at different parameters. Certain exemplary parameters comprise the depth of ultrasound energy 16 penetrations, the power supplied to each element 50, the frequency of operation of each element 50, the focal strength or “F Number,” the depth or focal depth, and energy. In one exemplary embodiment, transduction elements 50 are arranged in probe 26 in a specific manner to create a controlled, predictable emission of ultrasound energy 16. For example, a transducer can be constructed by providing elements to generate a known, predetermined pattern of ultrasound energy within ROI 12.
In another exemplary embodiment, transduction elements 50 are arranged within probe 26 to create a “cloud” of lesions within ROI 12 wherein each lesion has a different size and depth. According to this exemplary embodiment, different elements 50 are selected for their emission times, frequencies, focal depth, focal strength (F-number), energies and other relevant parameters discussed herein. The elements 50 are placed on a device that moves and enables the lesions to be placed at different locations within ROI 12 depending on the location of the elements relative to ROI 12.
In another exemplary embodiment, varying these parameters from one element 50 to another element 50 contained within probe 26 may create a pseudo random emission pattern of ultrasound energy 16. The creation of a pseudo random emission of ultrasound energy 16 creates a wide spatial and/or temporal band of therapeutic efficacy.
A time-temperature profile for the method can be modeled and optimized with the aid of the thermal dose concept. The thermal dose, or t43, is the exposure time at 43° C. which causes an equivalent biological effect due to an arbitrary time-temperature heating profile. Typically an ablative lesion forms on the order of one second at 56° C., which corresponds to a thermal dose of one hundred and twenty minutes at 43° C. The same thermal dose corresponds to 50° C. for approximately one minute. Thus a non-ablative profile can contain high temperatures for very short times and/or lower temperatures for longer times or a combination of various time-temperature profiles. For example, temperatures as high as 56° C. for under one second or 46° C. for under fifteen minutes can be utilized. Such processes can be implemented in various exemplary embodiments, whereby one or more profiles may be combined into a single treatment.
In an exemplary embodiment the temperature is raised to a high level, such as approximately 50° C. or more and held for several seconds. In another exemplary embodiment, the temperature is raised to a high level, (for example greater than 50° C.), for under one second up to five seconds or more, and then turned off for under one second up to five seconds or more, and repeated to create a pulsed profile.
In another exemplary embodiment, the temperature is raised quickly to a high level (greater than 50° C.), and then dropped to a lower temperature (less than 50° C.), and then maintained at that temperature for a given time period such as one second up to several seconds or over a minute.
In another exemplary embodiment, the temperature is increased quickly to a high level (THIGH), whereby THIGH is greater than 40° C., and the power to the system is turned off, but turned on again once the temperature drops below a lower threshold, (TLOW), whereby TLOW is less than THIGH. Once the temperature reaches THIGH again power to the system is turned back off and this process is repeated, in effect acting like a thermostat.
In another exemplary embodiment, the temperature is raised quickly to a high level (TSTART), whereby TSTART is greater than 40° C. and then turned off, but turned on again before the temperature drops appreciably (i.e. by a few degrees) below TSTART, whereby the temperature may then increase a small amount (i.e. by a few degrees) over TSTART before the power is turned off again. In such an exemplary embodiment the temperature quickly reaches a starting point and then may be allowed to increase to a higher temperature yet still remain in a non-ablative or coagulative regime before the treatment is ended.
Besides annular array 32 depicted in
The ultrasound energy 16 emitted can be emitted in various energy fields. The energy fields can be focused, defocused, and/or made substantially planar by the transducer to provide a plurality of different effects. Energy can be applied at one or more points in one or more C-planes or C-scans by automated or manual movement. For example, a substantially planar energy field can provide a heating and/or pretreatment effect, a focused energy field can provide a more concentrated source of heat or hyperthermal effect, and a non-focused energy field can provide diffused heating effects. It should be noted that the term “non-focused” as used throughout is meant to encompass energy that is unfocused or defocused.
An exemplary transducer emits ultrasound energy for imaging or treatment or a combination of both imaging and treatment. In an exemplary embodiment, the transducer is configured to emit ultrasound energy at specific depths in within ROI 12 as described above.
With reference to
In accordance with an exemplary embodiment, the transduction element 50 of the transducer can be configured to be uniform thereby having a narrowband resonance frequency distribution. In accordance with another exemplary embodiment, transduction element 50 can also be configured with a variable thickness, and/or as a multiple damped device, thereby having a wideband resonance frequency distribution. For example, transduction element 50 of the transducer can be configured to provide a center operating frequency of a lower range, for example from approximately 1 kHz to 3 MHz. Transduction element 50 can also be configured to provide a center operating frequency of a higher range, for example from approximately 3 to 100 MHz or more. In yet other exemplary embodiments, transduction element 50 is configured to emit ultrasound energy 16 at a frequency in the range of 1-15 MHz. In yet other exemplary embodiments, transduction element 50 is configured to emit ultrasound energy 16 at a frequency in the approximate range of 0.5 to 100 MHz, and in still yet other exemplary embodiments, transduction element 50 is configured to emit ultrasound energy at a frequency in the approximate range of 0.75 to 25 MHz. Other exemplary frequencies are in the approximate range of 0.75 MHz to 1.75 MHz. Harmonics and sub-harmonics can also be used in various embodiments of the present invention.
The transducer can be configured as a single broadband transducer excited with at least two or more frequencies such as 4 MHz and 7 MHz to provide an adequate output for raising the temperature and or causing the mechanical effects within the ROI to the desired level. The transducer can also be configured as two or more individual transducers, wherein each of the transducers comprises a separate transduction element 50.
Moreover, in an exemplary embodiment, any variety of mechanical lenses or variable focus lenses, e.g. liquid-filled lenses, may also be used to focus and or defocus the energy field. For example, the transducer may also be configured with an electronic focusing array in combination with one or more transduction elements 50 to facilitate increased flexibility in treating the ROI. The array may be configured in a manner similar to the transducer. That is, the array can be configured as an array of electronic apertures that may be operated by a variety of phases via variable electronic time delays, for example, T1, T2, T3 . . . Tj. By the term “operated,” the electronic apertures of the array may be manipulated, driven, used, and/or configured to produce and/or deliver energy in a manner corresponding to the phase variation caused by the electronic time delay. For example, these phase variations can be used to deliver defocused beams, planar beams, and/or focused beams, each of which may be used in combination to achieve different physiological effects in ROI 12.
Transduction elements 50 may be configured to be concave, convex, and/or planar. For example, in an exemplary embodiment depicted in
In one exemplary embodiment, transduction elements 50 are therapy line-focused single elements. Further, arrays 56, 58, 60, and 62 noted below may further comprise at least one imaging element 50 or a combination of imaging elements with treatment elements 50. In another exemplary embodiment, multiple-element, multiple-delay transducers 50 can be multiple-element, multiple-delay transducers perpendicular to those shown in
In another exemplary embodiment, depicted in
With reference to
With reference to
With reference now to
In an exemplary embodiment, an exemplary control system 28 is configured for coordination and control of the entire treatment process. For example, control system 28 can suitably comprise power source components 66, sensing and monitoring components 68, cooling and coupling controls 70, and/or processing and control logic components 72. Control system 28 can be configured and optimized in a variety of ways with more or less subsystems and components.
For example, control system 28 can comprise one or more direct current (DC) power supplies 74 configured to provide electrical energy for the entire control system, including power required by a transducer electronic amplifier/driver. A DC current sense device 76 can also be provided to confirm the level of power going into amplifiers/drivers for safety and monitoring purposes.
The amplifiers/drivers 78 can comprise multi-channel or single channel power amplifiers and/or drivers. In accordance with an exemplary embodiment for transducer array configurations, the amplifiers/drivers can also be configured with a beamformer to facilitate array focusing. An exemplary beamformer can be electrically excited by an oscillator/digitally controlled waveform synthesizer/oscillator 77 with related switching logic.
The power sourcing components can also include various filtering configurations 80. For example, switchable harmonic filters and/or matching may be used at the output of amplifier/driver/beamformer 78 to increase the drive efficiency and effectiveness. Power detection components 82 may also be included to confirm appropriate operation and calibration. For example, electric power and other energy detection components may be used to monitor the amount of power going to the probe.
Various sensing and monitoring components 84 may also be suitably implemented within the control system. For example, in accordance with an exemplary embodiment, the monitoring, sensing and interface control components 84 may be configured to operate with various motion detection systems implemented within the transducer to receive and process information such as acoustic or other spatial and/or temporal information from ROI 12. Sensing and monitoring components 84 can also include various controls, interfacing and switches 86 and/or power detectors. Such sensing and monitoring components can facilitate open-loop and/or closed-loop feedback systems within the system.
In an exemplary embodiment, the sensing and monitoring components comprise a sensor that is connected to an audio or visual alarm system to prevent overuse of the system. In this exemplary embodiment, the sensor senses the amount of energy transferred to the skin or the time that the system has be actively emitting energy. When a certain time or temperature threshold has been reached, the alarm sounds an audible alarm or causes a visual indicator to activate to alert the user that the threshold is reached. This prevents the user from overusing system. In an exemplary embodiment, the sensor could be operatively connected to the control system and force the control system to stop emitting ultrasound energy from the probe.
A cooling/coupling control system 88 may be provided to remove waste heat from an exemplary probe, provide a controlled temperature at the superficial tissue interface and deeper into tissue, and/or provide acoustic coupling from the probe to the ROI. Such cooling/coupling control systems can also be configured to operate in both open-loop and/or closed-loop feedback arrangements with various coupling and feedback components.
Additionally, an exemplary control system 28 can further comprise various system processor and digital control logic 90, such as one or more control or interfacing switches and associated components, including firmware and control software 92, which interfaces to user controls and interfacing circuits as well as input/output circuits and systems for communications, displays, interfacing, storage, documentation, and other useful functions. The system software controls all initialization, timing, level setting, monitoring, safety monitoring, and all other system functions required to accomplish user-defined treatment objectives. Further, various control switches can also be suitably configured to control operation. In an exemplary embodiment, control system 28 further comprises a mechanism and driver control 94.
With reference to
In addition, a microcontroller and timing circuits 106 with associated software and algorithms provide control and user interfacing via display 30, oscillator 107, and other input/output controls 109 such as switches and audio devices. A storage element 108, such as an EEPROM, secure EEPROM, tamper-proof EEPROM, or similar device holds calibration and usage data. A motion mechanism with feedback 110 can be suitably controlled to scan the transducer, if desirable, in a line or two-dimensional pattern and/or with variable depth. Other feedback controls include a capacitive, acoustic, force, or other coupling detection means and/or limiting controls and thermal sensor 111. A combination of the secure EEPROM with at least one of coupling caps, transducer, thermal sensor, coupling detectors, or tuning network along with a plastic or other housing can comprise a disposable tip.
With reference again to
Display 30 enables the user to facilitate localization of the treatment area and surrounding structures. After localization, delivery of ultrasound energy 16 at a depth, distribution, timing, and energy level to achieve the desired therapeutic effect is provided. Before, during, and/or after therapy, i.e., before, during and/or after delivery of ultrasound energy 16, monitoring of the treatment area and surrounding structures can be conducted to further plan and assess the results and/or providing feedback to the control system and a system operator via display 30.
In accordance with another exemplary embodiment of the present invention, an exemplary monitoring method may comprise monitoring the temperature profile or other tissue parameters of ROI 12 such as attenuation, speed of sound, or mechanical properties such as stiffness and strain of the treatment region and suitably adjust the spatial and/or temporal characteristics and energy levels of the ultrasound energy emitted from probe 26. The results of such monitoring techniques may be indicated on the display system by means of one-, two-, or three-dimensional images of monitoring results, or may simply comprise a success or fail-type indicator, or combinations thereof. Additional treatment monitoring techniques may be based on one or more of temperature, video, profilometry, and/or stiffness or strain gauges or any other suitable sensing technique.
In certain exemplary embodiments, system 10 is equipped with certain features to aid the user. One feature is a disposable tip that covers probe 26 during use. The disposable tip enables ultrasound energy 26 to pass through the tip and contact the patient. But, the disposable tip can be removed from probe 26 after use and replaced with a new disposable tip to prevent the spread of germs from one patient to another that might reside on the probe after contact with a patient's skin. Different size disposable tips can be used and fall within the scope of the present invention.
Present exemplary embodiments may be described herein in terms of various functional components and processing steps. It should be appreciated that such components and steps may be realized by any number of hardware components configured to perform the specified functions. For example, other exemplary embodiments may employ various medical treatment devices, visual imaging and display devices, input terminals and the like, which may carry out a variety of functions under the control of one or more control systems or other control devices. In addition, exemplary embodiments may be practiced in any number of medical contexts and that the exemplary embodiments relating to a system as described herein are merely indicative of exemplary applications for the disclosed subject matter. For example, the principles, features and methods discussed may be applied to any medical application. Further, various aspects of the present disclosure may be suitably applied to other applications, such as other medical or industrial applications.
This application claims priority to and the benefit of U.S. Provisional Patent Application No. 60/916,475 filed May 7, 2007 entitled “Method and System for Combined Energy Profile,” wherein such provisional application is hereby incorporated in its entirety, by reference and this application is a continuation-in-part of U.S. Patent Application assigned Ser. No. 10/944,500 entitled System and Method For Variable Depth Ultrasound Treatment that was filed on Sep. 16, 2004, wherein such application is incorporated in its entirety by reference.
Number | Name | Date | Kind |
---|---|---|---|
2427348 | Bond et al. | Sep 1947 | A |
3913386 | Saglio | Oct 1975 | A |
3965455 | Hurwitz | Jun 1976 | A |
3992925 | Perilhou | Nov 1976 | A |
4039312 | Patru | Aug 1977 | A |
4059098 | Murdock | Nov 1977 | A |
4101795 | Fukumoto | Jul 1978 | A |
4166967 | Benes et al. | Sep 1979 | A |
4211948 | Brisken et al. | Jul 1980 | A |
4211949 | Brisken et al. | Jul 1980 | A |
4213344 | Rose | Jul 1980 | A |
4276491 | Daniel | Jun 1981 | A |
4315514 | Drewes et al. | Feb 1982 | A |
4325381 | Glenn | Apr 1982 | A |
4343301 | Indech | Aug 1982 | A |
4372296 | Fahim | Feb 1983 | A |
4379145 | Masuho et al. | Apr 1983 | A |
4381007 | Doss | Apr 1983 | A |
4381787 | Hottinger | May 1983 | A |
4397314 | Vaguine | Aug 1983 | A |
4409839 | Taenzer | Oct 1983 | A |
4431008 | Wanner et al. | Feb 1984 | A |
4441486 | Pounds | Apr 1984 | A |
4452084 | Taenzer | Jun 1984 | A |
4484569 | Driller | Nov 1984 | A |
4507582 | Glenn | Mar 1985 | A |
4513749 | Kino et al. | Apr 1985 | A |
4513750 | Heyman et al. | Apr 1985 | A |
4527550 | Ruggera et al. | Jul 1985 | A |
4528979 | Marchenko | Jul 1985 | A |
4534221 | Fife et al. | Aug 1985 | A |
4566459 | Umemura et al. | Jan 1986 | A |
4567895 | Putzke | Feb 1986 | A |
4586512 | Do-Huu et al. | May 1986 | A |
4601296 | Yerushalmi | Jul 1986 | A |
4620546 | Aida et al. | Nov 1986 | A |
4637256 | Sugiyama et al. | Jan 1987 | A |
4646756 | Watmough | Mar 1987 | A |
4663358 | Hyon | May 1987 | A |
4668516 | Duraffourd et al. | May 1987 | A |
4672591 | Breimesser et al. | Jun 1987 | A |
4680499 | Umemura et al. | Jul 1987 | A |
4697588 | Reichenberger | Oct 1987 | A |
4754760 | Fukukita et al. | Jul 1988 | A |
4757820 | Itoh | Jul 1988 | A |
4771205 | Mequio | Sep 1988 | A |
4801459 | Liburdy | Jan 1989 | A |
4803625 | Fu et al. | Feb 1989 | A |
4807633 | Fry | Feb 1989 | A |
4817615 | Fukukita et al. | Apr 1989 | A |
4858613 | Fry et al. | Aug 1989 | A |
4860732 | Hasegawa et al. | Aug 1989 | A |
4865041 | Hassler | Sep 1989 | A |
4865042 | Umemura | Sep 1989 | A |
4867169 | Machida | Sep 1989 | A |
4874562 | Hyon | Oct 1989 | A |
4875487 | Seppi | Oct 1989 | A |
4891043 | Zeimer et al. | Jan 1990 | A |
4893624 | Lele | Jan 1990 | A |
4896673 | Rose | Jan 1990 | A |
4900540 | Ryan et al. | Feb 1990 | A |
4901729 | Saitoh et al. | Feb 1990 | A |
4917096 | Englehart et al. | Apr 1990 | A |
4973096 | Jaworski | Apr 1990 | A |
4932414 | Coleman et al. | Jun 1990 | A |
4938216 | Lele | Jul 1990 | A |
4938217 | Lele | Jul 1990 | A |
4947046 | Kawabata et al. | Aug 1990 | A |
4951653 | Fry et al. | Aug 1990 | A |
4955365 | Fry et al. | Sep 1990 | A |
4958626 | Nambu | Sep 1990 | A |
4976709 | Sand | Dec 1990 | A |
4979501 | Valchanov | Dec 1990 | A |
4992989 | Watanabe et al. | Feb 1991 | A |
5012797 | Liang | May 1991 | A |
5018508 | Fry et al. | May 1991 | A |
5030874 | Saito et al. | Jul 1991 | A |
5036855 | Fry et al. | Aug 1991 | A |
5040537 | Katakura | Aug 1991 | A |
5054310 | Flynn | Oct 1991 | A |
5054470 | Fry et al. | Oct 1991 | A |
5070879 | Herres | Dec 1991 | A |
5088495 | Miyagawa | Feb 1992 | A |
5115814 | Griffith | May 1992 | A |
5117832 | Sanghvi et al. | Jun 1992 | A |
5123418 | Saurel | Jun 1992 | A |
5143063 | Fellner | Sep 1992 | A |
5143074 | Dory | Sep 1992 | A |
5149319 | Unger | Sep 1992 | A |
5150711 | Dory | Sep 1992 | A |
5150714 | Green | Sep 1992 | A |
5152294 | Mochizuki et al. | Oct 1992 | A |
5156144 | Iwasaki et al. | Oct 1992 | A |
5158536 | Sekins | Oct 1992 | A |
5159931 | Pini | Nov 1992 | A |
5163421 | Bernstein et al. | Nov 1992 | A |
5163436 | Saitoh et al. | Nov 1992 | A |
5190518 | Takasu | Mar 1993 | A |
5190766 | Ishihara | Mar 1993 | A |
5191880 | McLeod et al. | Mar 1993 | A |
5205287 | Erbel et al. | Apr 1993 | A |
5209720 | Unger | May 1993 | A |
5212671 | Fujii et al. | May 1993 | A |
5215680 | D Arrigo | Jun 1993 | A |
5224467 | Oku | Jul 1993 | A |
5230334 | Klopotek | Jul 1993 | A |
5230338 | Allen et al. | Jul 1993 | A |
5247924 | Suzuki et al. | Sep 1993 | A |
5255681 | Ishimura et al. | Oct 1993 | A |
5257970 | Dougherty | Nov 1993 | A |
5265614 | Hayakawa | Nov 1993 | A |
5267985 | Shimada et al. | Dec 1993 | A |
5269297 | Weng | Dec 1993 | A |
5282797 | Chess | Feb 1994 | A |
5295484 | Marcus | Mar 1994 | A |
5295486 | Wollschlaeger et al. | Mar 1994 | A |
5304169 | Sand | Apr 1994 | A |
5305756 | Entrekin et al. | Apr 1994 | A |
5321520 | Inga et al. | Jun 1994 | A |
5323779 | Hardy et al. | Jun 1994 | A |
5327895 | Hashimoto et al. | Jul 1994 | A |
5348016 | Unger et al. | Sep 1994 | A |
5360268 | Hayashi | Nov 1994 | A |
5370121 | Reichenberger et al. | Dec 1994 | A |
5371483 | Bhardwaj | Dec 1994 | A |
5375602 | Lancee et al. | Dec 1994 | A |
5380280 | Peterson | Jan 1995 | A |
5380519 | Schneider et al. | Jan 1995 | A |
5391140 | Schaetzle | Feb 1995 | A |
5391197 | Burdette et al. | Feb 1995 | A |
5392259 | Bolorforosh | Feb 1995 | A |
5396143 | Seyed-Bolorforosh et al. | Mar 1995 | A |
5398689 | Connor et al. | Mar 1995 | A |
5406503 | Williams, Jr. et al. | Apr 1995 | A |
5417216 | Tanaka | May 1995 | A |
5419327 | Rohwedder et al. | May 1995 | A |
5423220 | Finsterwald et al. | Jun 1995 | A |
5435311 | Umemura | Jul 1995 | A |
5438998 | Hanafy | Aug 1995 | A |
5458596 | Lax et al. | Oct 1995 | A |
5460179 | Okunuki et al. | Oct 1995 | A |
5460595 | Hall et al. | Oct 1995 | A |
5469854 | Unger et al. | Nov 1995 | A |
5471988 | Fujio | Dec 1995 | A |
5487388 | Rello et al. | Jan 1996 | A |
5492126 | Hennige et al. | Feb 1996 | A |
5496256 | Bock | Mar 1996 | A |
5501655 | Rolt et al. | Mar 1996 | A |
5503152 | Oakley et al. | Apr 1996 | A |
5503320 | Webster et al. | Apr 1996 | A |
5507790 | Weiss | Apr 1996 | A |
5520188 | Hennige et al. | May 1996 | A |
5522869 | Burdette | Jun 1996 | A |
5523058 | Umemura et al. | Jun 1996 | A |
5524620 | Rosenschein | Jun 1996 | A |
5524624 | Tepper | Jun 1996 | A |
5524625 | Okazaki et al. | Jun 1996 | A |
5526624 | Berg | Jun 1996 | A |
5526812 | Dumoulin et al. | Jun 1996 | A |
5526814 | Cline et al. | Jun 1996 | A |
5526815 | Granz et al. | Jun 1996 | A |
5529070 | Augustine et al. | Jun 1996 | A |
5540235 | Wilson | Jul 1996 | A |
5558092 | Unger et al. | Sep 1996 | A |
5560362 | Sliwa et al. | Oct 1996 | A |
5575291 | Hayakawa | Nov 1996 | A |
5575807 | Faller | Nov 1996 | A |
5577502 | Darrow et al. | Nov 1996 | A |
5577507 | Snyder et al. | Nov 1996 | A |
5577991 | Akui et al. | Nov 1996 | A |
5580575 | Unger et al. | Dec 1996 | A |
5601526 | Chapelon et al. | Feb 1997 | A |
5603323 | Pflugrath et al. | Feb 1997 | A |
5609562 | Kaali | Mar 1997 | A |
5615091 | Palatnik | Mar 1997 | A |
5617858 | Taverna et al. | Apr 1997 | A |
5618275 | Bock | Apr 1997 | A |
5620479 | Diederich | Apr 1997 | A |
5622175 | Sudol et al. | Apr 1997 | A |
5638819 | Manwaring et al. | Jun 1997 | A |
5643179 | Fujimoto | Jul 1997 | A |
5644085 | Lorraine et al. | Jul 1997 | A |
5647373 | Paltieli | Jul 1997 | A |
5655535 | Friemel et al. | Aug 1997 | A |
5655538 | Lorraine | Aug 1997 | A |
5657760 | Ying | Aug 1997 | A |
5658328 | Johnson | Aug 1997 | A |
5660836 | Knowlton | Aug 1997 | A |
5662116 | Kondo et al. | Sep 1997 | A |
5665053 | Jacobs | Sep 1997 | A |
5665141 | Vago | Sep 1997 | A |
5671746 | Dreschel et al. | Sep 1997 | A |
5676692 | Sanghvi et al. | Oct 1997 | A |
5685820 | Riek et al. | Nov 1997 | A |
5687737 | Branham et al. | Nov 1997 | A |
5690608 | Watanabe | Nov 1997 | A |
5694936 | Fujimoto | Dec 1997 | A |
5697897 | Buchholtz | Dec 1997 | A |
5701900 | Shehada et al. | Dec 1997 | A |
5704361 | Seward et al. | Jan 1998 | A |
5706252 | Le Verrier et al. | Jan 1998 | A |
5706564 | Rhyne | Jan 1998 | A |
5715823 | Wood et al. | Feb 1998 | A |
5720287 | Chapelon et al. | Feb 1998 | A |
5722411 | Suzuki | Mar 1998 | A |
5727554 | Kalend et al. | Mar 1998 | A |
5735280 | Sherman et al. | Apr 1998 | A |
5743863 | Chapelon | Apr 1998 | A |
5746005 | Steinberg | May 1998 | A |
5746762 | Bass | May 1998 | A |
5748767 | Raab | May 1998 | A |
5749364 | Sliwa et al. | May 1998 | A |
5755228 | Wilson et al. | May 1998 | A |
5755753 | Knowlton | May 1998 | A |
5762066 | Law et al. | Jun 1998 | A |
5763886 | Schulte | Jun 1998 | A |
5769790 | Watkins et al. | Jun 1998 | A |
5779644 | Eberle et al. | Jul 1998 | A |
5792058 | Lee et al. | Aug 1998 | A |
5795297 | Daigle | Aug 1998 | A |
5795311 | Wess | Aug 1998 | A |
5810009 | Mine et al. | Sep 1998 | A |
5810888 | Fenn | Sep 1998 | A |
5814599 | Mitragotri et al. | Sep 1998 | A |
5817013 | Ginn et al. | Oct 1998 | A |
5817021 | Reichenberger | Oct 1998 | A |
5820564 | Slayton et al. | Oct 1998 | A |
5823962 | Schaetzle | Oct 1998 | A |
5827204 | Grandia et al. | Oct 1998 | A |
5840032 | Hatfield et al. | Nov 1998 | A |
5844140 | Seale | Dec 1998 | A |
5853367 | Chalek et al. | Dec 1998 | A |
5869751 | Bonin | Feb 1999 | A |
5871524 | Knowlton | Feb 1999 | A |
5873902 | Sanghvi et al. | Feb 1999 | A |
5876431 | Spehr et al. | Mar 1999 | A |
5879303 | Averkiou et al. | Mar 1999 | A |
5882557 | Hayakawa | Mar 1999 | A |
5891034 | Bucholz | Apr 1999 | A |
5899861 | Friemel et al. | May 1999 | A |
5904659 | Duarte et al. | May 1999 | A |
5919219 | Knowlton | Jul 1999 | A |
5923099 | Bilir | Jul 1999 | A |
5924989 | Polz | Jul 1999 | A |
5928169 | Schatzle et al. | Jul 1999 | A |
5931805 | Brisken | Aug 1999 | A |
5938606 | Bonnefous | Aug 1999 | A |
5938612 | Kline-Schoder et al. | Aug 1999 | A |
5948011 | Knowlton | Sep 1999 | A |
5957844 | Dekel | Sep 1999 | A |
5957882 | Nita et al. | Sep 1999 | A |
5957941 | Ream | Sep 1999 | A |
5967980 | Ferre et al. | Oct 1999 | A |
5968034 | Fullmer et al. | Oct 1999 | A |
5971949 | Levin | Oct 1999 | A |
5977538 | Unger et al. | Nov 1999 | A |
5984882 | Rosenschein | Nov 1999 | A |
5990598 | Sudol et al. | Nov 1999 | A |
5997471 | Gumb et al. | Dec 1999 | A |
5997497 | Nita et al. | Dec 1999 | A |
5999843 | Anbar | Dec 1999 | A |
6004262 | Putz et al. | Dec 1999 | A |
6007499 | Martin et al. | Dec 1999 | A |
6013032 | Savord | Jan 2000 | A |
6016255 | Bolan et al. | Jan 2000 | A |
6019724 | Gronningsaeter et al. | Feb 2000 | A |
6022308 | Williams | Feb 2000 | A |
6036646 | Barthe et al. | Mar 2000 | A |
6039048 | Silberg | Mar 2000 | A |
6039689 | Lizzi | Mar 2000 | A |
6042556 | Beach et al. | Mar 2000 | A |
6049159 | Barthe et al. | Apr 2000 | A |
6050943 | Slayton et al. | Apr 2000 | A |
6059727 | Fowlkes | May 2000 | A |
6071239 | Cribbs et al. | Jun 2000 | A |
6080108 | Dunham | Jun 2000 | A |
6083148 | Williams | Jul 2000 | A |
6086535 | Ishibashi | Jul 2000 | A |
6086580 | Mordon et al. | Jul 2000 | A |
6090054 | Tagishi | Jul 2000 | A |
6093883 | Sanghvi et al. | Jul 2000 | A |
6101407 | Groezinger | Aug 2000 | A |
6106469 | Suzuki et al. | Aug 2000 | A |
6113558 | Rosenschein | Sep 2000 | A |
6113559 | Klopotek | Sep 2000 | A |
6120452 | Barthe et al. | Sep 2000 | A |
6123081 | Durette | Sep 2000 | A |
6126619 | Peterson et al. | Oct 2000 | A |
6135971 | Hutchinson et al. | Oct 2000 | A |
6139499 | Wilk | Oct 2000 | A |
6159150 | Yale et al. | Dec 2000 | A |
6171244 | Finger et al. | Jan 2001 | B1 |
6176840 | Nishimura | Jan 2001 | B1 |
6183426 | Akisada et al. | Feb 2001 | B1 |
6183502 | Takeuchi | Feb 2001 | B1 |
6183773 | Anderson | Feb 2001 | B1 |
6190323 | Dias et al. | Feb 2001 | B1 |
6190336 | Duarte et al. | Feb 2001 | B1 |
6193658 | Wendelken et al. | Feb 2001 | B1 |
6210327 | Brackett et al. | Apr 2001 | B1 |
6213948 | Barthe et al. | Apr 2001 | B1 |
6216029 | Paltieli | Apr 2001 | B1 |
6233476 | Strommer et al. | May 2001 | B1 |
6234990 | Rowe et al. | May 2001 | B1 |
6241753 | Knowlton | Jun 2001 | B1 |
6246898 | Vesely et al. | Jun 2001 | B1 |
6251088 | Kaufman et al. | Jun 2001 | B1 |
6268405 | Yao | Jul 2001 | B1 |
6273864 | Duarte et al. | Aug 2001 | B1 |
6280402 | Ishibashi et al. | Aug 2001 | B1 |
6287257 | Matichuk | Sep 2001 | B1 |
6296619 | Brisken | Oct 2001 | B1 |
6301989 | Brown et al. | Oct 2001 | B1 |
6309355 | Cain et al. | Oct 2001 | B1 |
6311090 | Knowlton | Oct 2001 | B1 |
6315741 | Martin et al. | Nov 2001 | B1 |
6322509 | Pan et al. | Nov 2001 | B1 |
6322532 | D'Sa | Nov 2001 | B1 |
6325540 | Lounsberry et al. | Dec 2001 | B1 |
6325758 | Carol et al. | Dec 2001 | B1 |
6325769 | Klopotek | Dec 2001 | B1 |
6325798 | Edwards et al. | Dec 2001 | B1 |
6338716 | Hossack et al. | Jan 2002 | B1 |
6350276 | Knowlton | Feb 2002 | B1 |
6356780 | Licato et al. | Mar 2002 | B1 |
6361531 | Hissong | Mar 2002 | B1 |
6370411 | Osadchy et al. | Apr 2002 | B1 |
6375672 | Aksan et al. | Apr 2002 | B1 |
6377854 | Knowlton | Apr 2002 | B1 |
6377855 | Knowlton | Apr 2002 | B1 |
6381497 | Knowlton | Apr 2002 | B1 |
6381498 | Knowlton | Apr 2002 | B1 |
6387380 | Knowlton | May 2002 | B1 |
6390982 | Bova et al. | May 2002 | B1 |
6405090 | Knowlton | Jun 2002 | B1 |
6409720 | Hissong et al. | Jun 2002 | B1 |
6413216 | Cain et al. | Jul 2002 | B1 |
6413253 | Koop et al. | Jul 2002 | B1 |
6413254 | Hissong et al. | Jul 2002 | B1 |
6419648 | Vitek et al. | Jul 2002 | B1 |
6423007 | Lizzi et al. | Jul 2002 | B2 |
6425865 | Salcudean et al. | Jul 2002 | B1 |
6425867 | Vaezy et al. | Jul 2002 | B1 |
6425912 | Knowlton | Jul 2002 | B1 |
6428477 | Mason | Aug 2002 | B1 |
6428532 | Doukas et al. | Aug 2002 | B1 |
6430446 | Knowlton | Aug 2002 | B1 |
6432057 | Mazess et al. | Aug 2002 | B1 |
6432067 | Martin et al. | Aug 2002 | B1 |
6432101 | Weber et al. | Aug 2002 | B1 |
6436061 | Costantino | Aug 2002 | B1 |
6438424 | Knowlton | Aug 2002 | B1 |
6440071 | Slayton et al. | Aug 2002 | B1 |
6443914 | Costantino | Sep 2002 | B1 |
6453202 | Knowlton | Sep 2002 | B1 |
6461378 | Knowlton | Oct 2002 | B1 |
6470216 | Knowlton | Oct 2002 | B1 |
6488626 | Lizzi et al. | Dec 2002 | B1 |
6491657 | Rowe | Dec 2002 | B2 |
6500121 | Slayton et al. | Dec 2002 | B1 |
6500141 | Irion et al. | Dec 2002 | B1 |
6508774 | Acker | Jan 2003 | B1 |
6511427 | Sliwa, Jr. et al. | Jan 2003 | B1 |
6511428 | Azuma | Jan 2003 | B1 |
6514244 | Pope et al. | Feb 2003 | B2 |
6517484 | Wilk et al. | Feb 2003 | B1 |
6524250 | Weber | Feb 2003 | B1 |
6540679 | Slayton et al. | Apr 2003 | B2 |
6540685 | Rhoads et al. | Apr 2003 | B1 |
6540700 | Fujimoto et al. | Apr 2003 | B1 |
6554771 | Buil et al. | Apr 2003 | B1 |
6569099 | Babaev | May 2003 | B1 |
6569108 | Sarvazyan et al. | May 2003 | B2 |
6572552 | Fukukita | Jun 2003 | B2 |
6575956 | Brisken et al. | Jun 2003 | B1 |
6595934 | Hissong et al. | Jul 2003 | B1 |
6599256 | Acker | Jul 2003 | B1 |
6607498 | Eshel | Aug 2003 | B2 |
6618620 | Freundlich et al. | Sep 2003 | B1 |
6623430 | Slayton et al. | Sep 2003 | B1 |
6626854 | Friedman et al. | Sep 2003 | B2 |
6626855 | Weng et al. | Sep 2003 | B1 |
6663627 | He et al. | Oct 2003 | B2 |
6645162 | Friedman et al. | Nov 2003 | B2 |
6662054 | Kreindel | Dec 2003 | B2 |
6665806 | Shimizu | Dec 2003 | B1 |
6666835 | Martin | Dec 2003 | B2 |
6669638 | Miller et al. | Dec 2003 | B1 |
6685640 | Fry et al. | Feb 2004 | B1 |
6692450 | Coleman | Feb 2004 | B1 |
6699237 | Weber | Mar 2004 | B2 |
6716184 | Vaezy et al. | Apr 2004 | B2 |
6719449 | Laughlin | Apr 2004 | B1 |
6719694 | Weng et al. | Apr 2004 | B2 |
6726627 | Lizzi et al. | Apr 2004 | B1 |
6733449 | Krishnamurthy et al. | May 2004 | B1 |
6749624 | Knowlton | Jun 2004 | B2 |
6773409 | Truckai et al. | Aug 2004 | B2 |
6775404 | Pagoulatos et al. | Aug 2004 | B1 |
6790187 | Thompson et al. | Sep 2004 | B2 |
6824516 | Batten et al. | Nov 2004 | B2 |
6835940 | Morikawa et al. | Dec 2004 | B2 |
6846290 | Lizzi et al. | Jan 2005 | B2 |
6875176 | Mourad | Apr 2005 | B2 |
6887239 | Elstrom et al. | May 2005 | B2 |
6889089 | Behl | May 2005 | B2 |
6896657 | Willis | May 2005 | B2 |
6902536 | Manna | Jun 2005 | B2 |
6905466 | Salgo | Jun 2005 | B2 |
6918907 | Kelly | Jul 2005 | B2 |
6920883 | Bessette | Jul 2005 | B2 |
6921371 | Wilson | Jul 2005 | B2 |
6932771 | Whitmore | Aug 2005 | B2 |
6932814 | Wood | Aug 2005 | B2 |
6936044 | McDaniel | Aug 2005 | B2 |
6936046 | Hissong et al. | Aug 2005 | B2 |
6945937 | Culp et al. | Sep 2005 | B2 |
6948843 | Laugharn et al. | Sep 2005 | B2 |
6953941 | Nakano et al. | Oct 2005 | B2 |
6958043 | Hissong | Oct 2005 | B2 |
6974417 | Lockwood | Dec 2005 | B2 |
6976492 | Ingle | Dec 2005 | B2 |
6992305 | Maezawa et al. | Jan 2006 | B2 |
6997923 | Anderson et al. | Feb 2006 | B2 |
7006874 | Knowlton | Feb 2006 | B2 |
7020528 | Neev | Mar 2006 | B2 |
7022089 | Ooba | Apr 2006 | B2 |
7058440 | Heuscher et al. | Jun 2006 | B2 |
7063666 | Weng et al. | Jun 2006 | B2 |
7070565 | Vaezy et al. | Jul 2006 | B2 |
7074218 | Washington et al. | Jul 2006 | B2 |
7094252 | Koop | Aug 2006 | B2 |
7108663 | Talish et al. | Sep 2006 | B2 |
7115123 | Knowlton | Oct 2006 | B2 |
7122029 | Koop et al. | Oct 2006 | B2 |
7142905 | Slayton et al. | Nov 2006 | B2 |
7165451 | Brooks et al. | Jan 2007 | B1 |
7179238 | Hissong | Feb 2007 | B2 |
7189230 | Knowlton | Mar 2007 | B2 |
7229411 | Slayton et al. | Jun 2007 | B2 |
7235592 | Muratoglu | Jun 2007 | B2 |
7258674 | Cribbs et al. | Aug 2007 | B2 |
7273459 | Desilets | Sep 2007 | B2 |
7294125 | Phalen et al. | Nov 2007 | B2 |
7297117 | Trucco et al. | Nov 2007 | B2 |
7303555 | Makin et al. | Dec 2007 | B2 |
7327071 | Nishiyama et al. | Feb 2008 | B2 |
7331951 | Eshel et al. | Feb 2008 | B2 |
7332985 | Larson, III et al. | Feb 2008 | B2 |
7347855 | Eshel | Mar 2008 | B2 |
RE40403 | Cho et al. | Jun 2008 | E |
7393325 | Barthe et al. | Jul 2008 | B2 |
7398116 | Edwards | Jul 2008 | B2 |
7399279 | Abend et al. | Jul 2008 | B2 |
7510536 | Foley et al. | Mar 2009 | B2 |
7530356 | Slayton | May 2009 | B2 |
7530958 | Slayton | May 2009 | B2 |
7571336 | Barthe | Aug 2009 | B2 |
7601120 | Moilanen et al. | Oct 2009 | B2 |
7615015 | Coleman | Nov 2009 | B2 |
7615016 | Barthe | Nov 2009 | B2 |
7686763 | Vaezy et al. | Mar 2010 | B2 |
7695437 | Quistgaard et al. | Apr 2010 | B2 |
7758524 | Barthe | Jul 2010 | B2 |
7789841 | Huckle et al. | Sep 2010 | B2 |
7824348 | Barthe et al. | Nov 2010 | B2 |
7846096 | Mast et al. | Dec 2010 | B2 |
7857773 | Desilets et al. | Dec 2010 | B2 |
7875023 | Eshel et al. | Jan 2011 | B2 |
7914453 | Slayton et al. | Mar 2011 | B2 |
7914469 | Torbati | Mar 2011 | B2 |
7931611 | Novak et al. | Apr 2011 | B2 |
7955281 | Pedersen et al. | Jun 2011 | B2 |
7967839 | Flock et al. | Jun 2011 | B2 |
8057389 | Barthe et al. | Nov 2011 | B2 |
8057465 | Sliwa, Jr. et al. | Nov 2011 | B2 |
8066641 | Barthe et al. | Nov 2011 | B2 |
8123707 | Huckle et al. | Feb 2012 | B2 |
8128618 | Gliklich et al. | Mar 2012 | B2 |
8133180 | Slayton et al. | Mar 2012 | B2 |
8133191 | Rosenberg et al. | Mar 2012 | B2 |
8197409 | Foley et al. | Jun 2012 | B2 |
8206299 | Foley et al. | Jun 2012 | B2 |
8211017 | Foley et al. | Jul 2012 | B2 |
8262591 | Pedersen et al. | Sep 2012 | B2 |
8273037 | Kreindel et al. | Sep 2012 | B2 |
8282554 | Makin et al. | Oct 2012 | B2 |
8333700 | Barthe et al. | Dec 2012 | B1 |
8366622 | Slayton et al. | Feb 2013 | B2 |
8409097 | Slayton et al. | Apr 2013 | B2 |
8444562 | Barthe et al. | May 2013 | B2 |
8480585 | Slayton et al. | Jul 2013 | B2 |
8506486 | Slayton et al. | Aug 2013 | B2 |
8523775 | Barthe et al. | Sep 2013 | B2 |
8535228 | Slayton et al. | Sep 2013 | B2 |
8585618 | Hunziker et al. | Nov 2013 | B2 |
8636665 | Slayton et al. | Jan 2014 | B2 |
8641622 | Barthe et al. | Feb 2014 | B2 |
8663112 | Slayton et al. | Mar 2014 | B2 |
8672848 | Slayton et al. | Mar 2014 | B2 |
8690778 | Slayton et al. | Apr 2014 | B2 |
8690779 | Slayton et al. | Apr 2014 | B2 |
8690780 | Slayton et al. | Apr 2014 | B2 |
8708935 | Barthe et al. | Apr 2014 | B2 |
8715186 | Slayton et al. | May 2014 | B2 |
8726781 | Eckhoff et al. | May 2014 | B2 |
20010009997 | Pope et al. | Jul 2001 | A1 |
20010009999 | Kaufman et al. | Jul 2001 | A1 |
20010014780 | Martin et al. | Aug 2001 | A1 |
20010014819 | Ingle et al. | Aug 2001 | A1 |
20010031922 | Weng et al. | Oct 2001 | A1 |
20010039380 | Larson et al. | Nov 2001 | A1 |
20010041880 | Brisken | Nov 2001 | A1 |
20020000763 | Jones | Jan 2002 | A1 |
20020002345 | Marlinghaus | Jan 2002 | A1 |
20020040199 | Klopotek | Apr 2002 | A1 |
20020040442 | Ishidera | Apr 2002 | A1 |
20020052550 | Madsen et al. | May 2002 | A1 |
20020055702 | Atala | May 2002 | A1 |
20020062077 | Emmenegger et al. | May 2002 | A1 |
20020062142 | Knowlton | May 2002 | A1 |
20020072691 | Thompson et al. | Jun 2002 | A1 |
20020082528 | Friedman et al. | Jun 2002 | A1 |
20020082529 | Suorsa et al. | Jun 2002 | A1 |
20020082589 | Friedman et al. | Jun 2002 | A1 |
20020087080 | Slayton et al. | Jul 2002 | A1 |
20020095143 | Key | Jul 2002 | A1 |
20020099094 | Anderson | Jul 2002 | A1 |
20020115917 | Honda et al. | Aug 2002 | A1 |
20020128648 | Weber | Sep 2002 | A1 |
20020143252 | Dunne et al. | Oct 2002 | A1 |
20020156400 | Babaev | Oct 2002 | A1 |
20020161357 | Anderson et al. | Oct 2002 | A1 |
20020165529 | Danek | Nov 2002 | A1 |
20020168049 | Schriever et al. | Nov 2002 | A1 |
20020169394 | Eppstein et al. | Nov 2002 | A1 |
20020169442 | Neev | Nov 2002 | A1 |
20020173721 | Grunwald et al. | Nov 2002 | A1 |
20020193784 | Mchale et al. | Dec 2002 | A1 |
20020193831 | Smith | Dec 2002 | A1 |
20030009153 | Brisken et al. | Jan 2003 | A1 |
20030014039 | Barzell et al. | Jan 2003 | A1 |
20030018255 | Martin | Jan 2003 | A1 |
20030028111 | Vaezy et al. | Feb 2003 | A1 |
20030028113 | Gilbert et al. | Feb 2003 | A1 |
20030032900 | Ella | Feb 2003 | A1 |
20030036706 | Slayton et al. | Feb 2003 | A1 |
20030040739 | Koop | Feb 2003 | A1 |
20030050678 | Sierra | Mar 2003 | A1 |
20030055417 | Truckai et al. | Mar 2003 | A1 |
20030060736 | Martin et al. | Mar 2003 | A1 |
20030065313 | Koop | Apr 2003 | A1 |
20030074023 | Kaplan | Apr 2003 | A1 |
20030083536 | Eshel et al. | May 2003 | A1 |
20030092988 | Makin | May 2003 | A1 |
20030097071 | Halmann et al. | May 2003 | A1 |
20030099383 | Lefebvre | May 2003 | A1 |
20030125629 | Ustuner | Jul 2003 | A1 |
20030139790 | Ingle et al. | Jul 2003 | A1 |
20030171678 | Batten et al. | Sep 2003 | A1 |
20030171701 | Babaev | Sep 2003 | A1 |
20030176790 | Slayton | Sep 2003 | A1 |
20030191396 | Sanghvi et al. | Oct 2003 | A1 |
20030200481 | Stanley | Oct 2003 | A1 |
20030212129 | Liu et al. | Nov 2003 | A1 |
20030212351 | Hissong et al. | Nov 2003 | A1 |
20030212393 | Knowlton et al. | Nov 2003 | A1 |
20030216795 | Harth et al. | Nov 2003 | A1 |
20030220536 | Hissong | Nov 2003 | A1 |
20030220585 | Hissong | Nov 2003 | A1 |
20030229331 | Brisken et al. | Dec 2003 | A1 |
20030236487 | Knowlton | Dec 2003 | A1 |
20040000316 | Knowlton | Jan 2004 | A1 |
20040001809 | Brisken | Jan 2004 | A1 |
20040002705 | Knowlton | Jan 2004 | A1 |
20040010222 | Nunomura et al. | Jan 2004 | A1 |
20040015106 | Coleman | Jan 2004 | A1 |
20040015559 | Goldstein | Jan 2004 | A1 |
20040030227 | Littrup et al. | Feb 2004 | A1 |
20040039312 | Hillstead et al. | Feb 2004 | A1 |
20040039418 | Elstrom et al. | Feb 2004 | A1 |
20040041563 | Lewin et al. | Mar 2004 | A1 |
20040042168 | Yang et al. | Mar 2004 | A1 |
20040044375 | Diederich et al. | Mar 2004 | A1 |
20040049134 | Tosaya et al. | Mar 2004 | A1 |
20040049734 | Simske | Mar 2004 | A1 |
20040059266 | Fry et al. | Mar 2004 | A1 |
20040068186 | Ishida et al. | Apr 2004 | A1 |
20040073079 | Altshuler et al. | Apr 2004 | A1 |
20040073113 | Salgo et al. | Apr 2004 | A1 |
20040073115 | Horzewski et al. | Apr 2004 | A1 |
20040073116 | Smith | Apr 2004 | A1 |
20040077977 | Ella et al. | Apr 2004 | A1 |
20040082857 | Schonenberger et al. | Apr 2004 | A1 |
20040082859 | Schaer | Apr 2004 | A1 |
20040102697 | Evron | May 2004 | A1 |
20040122323 | Vortman et al. | Jun 2004 | A1 |
20040122493 | Ishibashi et al. | Jun 2004 | A1 |
20040143297 | Ramsey | Jul 2004 | A1 |
20040152982 | Hwang et al. | Aug 2004 | A1 |
20040158150 | Rabiner et al. | Aug 2004 | A1 |
20040186535 | Knowlton | Sep 2004 | A1 |
20040189155 | Funakubo | Sep 2004 | A1 |
20040206365 | Knowlton | Oct 2004 | A1 |
20040210214 | Knowlton | Oct 2004 | A1 |
20040217675 | Desilets | Nov 2004 | A1 |
20040249318 | Tanaka | Dec 2004 | A1 |
20040254620 | Lacoste et al. | Dec 2004 | A1 |
20040267252 | Washington et al. | Dec 2004 | A1 |
20050033201 | Takahashi | Feb 2005 | A1 |
20050033316 | Kertz | Feb 2005 | A1 |
20050038340 | Vaezy et al. | Feb 2005 | A1 |
20050055073 | Weber | Mar 2005 | A1 |
20050061834 | Garcia et al. | Mar 2005 | A1 |
20050070961 | Maki et al. | Mar 2005 | A1 |
20050074407 | Smith | Apr 2005 | A1 |
20050080469 | Larson et al. | Apr 2005 | A1 |
20050091770 | Mourad et al. | May 2005 | A1 |
20050096542 | Weng et al. | May 2005 | A1 |
20050104690 | Larson, III et al. | May 2005 | A1 |
20050113689 | Gritzky | May 2005 | A1 |
20050134314 | Prather et al. | Jun 2005 | A1 |
20050137656 | Malak | Jun 2005 | A1 |
20050143677 | Young et al. | Jun 2005 | A1 |
20050154313 | Desilets | Jul 2005 | A1 |
20050154314 | Quistgaard | Jul 2005 | A1 |
20050154332 | Zanelli | Jul 2005 | A1 |
20050154431 | Quistgaard | Jul 2005 | A1 |
20050187495 | Quistgaard et al. | Aug 2005 | A1 |
20050191252 | Mitsui | Sep 2005 | A1 |
20050193451 | Quistgaard et al. | Sep 2005 | A1 |
20050197681 | Barolet et al. | Sep 2005 | A1 |
20050228281 | Nefos | Oct 2005 | A1 |
20050240170 | Zhang et al. | Oct 2005 | A1 |
20050251120 | Anderson et al. | Nov 2005 | A1 |
20050256406 | Barthe et al. | Nov 2005 | A1 |
20050261584 | Eshel | Nov 2005 | A1 |
20050261585 | Makin et al. | Nov 2005 | A1 |
20050267454 | Hissong et al. | Dec 2005 | A1 |
20050288748 | Li et al. | Dec 2005 | A1 |
20060004306 | Altshuler | Jan 2006 | A1 |
20060020260 | Dover et al. | Jan 2006 | A1 |
20060025756 | Francischelli | Feb 2006 | A1 |
20060042201 | Curry | Mar 2006 | A1 |
20060058664 | Barthe | Mar 2006 | A1 |
20060058707 | Barthe et al. | Mar 2006 | A1 |
20060058712 | Altshuler et al. | Mar 2006 | A1 |
20060074309 | Bonnefous | Apr 2006 | A1 |
20060074313 | Slayton et al. | Apr 2006 | A1 |
20060074314 | Slayton et al. | Apr 2006 | A1 |
20060074355 | Slayton et al. | Apr 2006 | A1 |
20060079816 | Barthe et al. | Apr 2006 | A1 |
20060079868 | Makin et al. | Apr 2006 | A1 |
20060084891 | Barthe et al. | Apr 2006 | A1 |
20060089632 | Barthe et al. | Apr 2006 | A1 |
20060089688 | Panescu | Apr 2006 | A1 |
20060094988 | Tosaya et al. | May 2006 | A1 |
20060111744 | Makin et al. | May 2006 | A1 |
20060116583 | Ogasawara et al. | Jun 2006 | A1 |
20060116671 | Slayton et al. | Jun 2006 | A1 |
20060122508 | Slayton | Jun 2006 | A1 |
20060122509 | Slayton et al. | Jun 2006 | A1 |
20060161062 | Arditi et al. | Jul 2006 | A1 |
20060184069 | Vaitekunas | Aug 2006 | A1 |
20060184071 | Klopotek | Aug 2006 | A1 |
20060189972 | Grossman | Aug 2006 | A1 |
20060206105 | Chopra et al. | Sep 2006 | A1 |
20060229514 | Wiener | Oct 2006 | A1 |
20060241440 | Eshel | Oct 2006 | A1 |
20060241442 | Barthe et al. | Oct 2006 | A1 |
20060241470 | Novak et al. | Oct 2006 | A1 |
20060250046 | Koizumi et al. | Nov 2006 | A1 |
20060282691 | Barthe et al. | Dec 2006 | A1 |
20060291710 | Wang et al. | Dec 2006 | A1 |
20070032784 | Gliklich et al. | Feb 2007 | A1 |
20070035201 | Desilets | Feb 2007 | A1 |
20070055154 | Torbati | Mar 2007 | A1 |
20070055155 | Owen et al. | Mar 2007 | A1 |
20070055156 | Desilets et al. | Mar 2007 | A1 |
20070065420 | Johnson | Mar 2007 | A1 |
20070083120 | Cain et al. | Apr 2007 | A1 |
20070087060 | Dietrich | Apr 2007 | A1 |
20070088245 | Babaev et al. | Apr 2007 | A1 |
20070088346 | Mirizzi et al. | Apr 2007 | A1 |
20070166357 | Shaffer et al. | Jul 2007 | A1 |
20070167709 | Slayton et al. | Jul 2007 | A1 |
20070208253 | Slayton et al. | Sep 2007 | A1 |
20070219604 | Yaroslavsky et al. | Sep 2007 | A1 |
20070219605 | Yaroslavsky et al. | Sep 2007 | A1 |
20070238994 | Stecco et al. | Oct 2007 | A1 |
20070239075 | Rosenberg et al. | Oct 2007 | A1 |
20070239079 | Manstein et al. | Oct 2007 | A1 |
20070239142 | Altshuler et al. | Oct 2007 | A1 |
20080027328 | Klopotek et al. | Jan 2008 | A1 |
20080039724 | Seip et al. | Feb 2008 | A1 |
20080071255 | Barthe et al. | Mar 2008 | A1 |
20080086054 | Slayton et al. | Apr 2008 | A1 |
20080097253 | Pederson | Apr 2008 | A1 |
20080139974 | Da Silva | Jun 2008 | A1 |
20080146970 | Litman et al. | Jun 2008 | A1 |
20080167556 | Thompson et al. | Jul 2008 | A1 |
20080183077 | Moreau-Gobard et al. | Jul 2008 | A1 |
20080188745 | Chen et al. | Aug 2008 | A1 |
20080195000 | Spooner et al. | Aug 2008 | A1 |
20080200810 | Buchalter | Aug 2008 | A1 |
20080200813 | Quistgaard | Aug 2008 | A1 |
20080214966 | Slayton et al. | Sep 2008 | A1 |
20080221491 | Slayton et al. | Sep 2008 | A1 |
20080223379 | Stuker et al. | Sep 2008 | A1 |
20080243035 | Crunkilton | Oct 2008 | A1 |
20080269608 | Anderson et al. | Oct 2008 | A1 |
20080275342 | Barthe et al. | Nov 2008 | A1 |
20080281206 | Bartlett et al. | Nov 2008 | A1 |
20080281236 | Eshel et al. | Nov 2008 | A1 |
20080281237 | Slayton et al. | Nov 2008 | A1 |
20080281255 | Slayton et al. | Nov 2008 | A1 |
20080294073 | Barthe et al. | Nov 2008 | A1 |
20080319356 | Cain et al. | Dec 2008 | A1 |
20090005680 | Jones et al. | Jan 2009 | A1 |
20090012394 | Hobelsberger et al. | Jan 2009 | A1 |
20090043198 | Milner et al. | Feb 2009 | A1 |
20090043293 | Pankratov et al. | Feb 2009 | A1 |
20090069677 | Chen et al. | Mar 2009 | A1 |
20090093737 | Chomas et al. | Apr 2009 | A1 |
20090156969 | Santangelo | Jun 2009 | A1 |
20090171252 | Bockenstedt et al. | Jul 2009 | A1 |
20090177122 | Peterson | Jul 2009 | A1 |
20090177123 | Peterson | Jul 2009 | A1 |
20090182231 | Barthe et al. | Jul 2009 | A1 |
20090216159 | Slayton et al. | Aug 2009 | A1 |
20090226424 | Hsu | Sep 2009 | A1 |
20090227910 | Pedersen et al. | Sep 2009 | A1 |
20090253988 | Slayton et al. | Oct 2009 | A1 |
20090299175 | Bernstein et al. | Dec 2009 | A1 |
20090318909 | Debenedictis et al. | Dec 2009 | A1 |
20100011236 | Barthe et al. | Jan 2010 | A1 |
20100022919 | Peterson | Jan 2010 | A1 |
20100022922 | Barthe et al. | Jan 2010 | A1 |
20100042020 | Ben-Ezra | Feb 2010 | A1 |
20100049178 | Deem et al. | Feb 2010 | A1 |
20100063422 | Hynynen et al. | Mar 2010 | A1 |
20100130891 | Taggart et al. | May 2010 | A1 |
20100160782 | Slayton et al. | Jun 2010 | A1 |
20100160837 | Hunziker et al. | Jun 2010 | A1 |
20100168576 | Poland et al. | Jul 2010 | A1 |
20100191120 | Kraus et al. | Jul 2010 | A1 |
20100241035 | Barthe et al. | Sep 2010 | A1 |
20100280420 | Barthe et al. | Nov 2010 | A1 |
20100286518 | Lee et al. | Nov 2010 | A1 |
20110040171 | Foley et al. | Feb 2011 | A1 |
20110040190 | Jahnke et al. | Feb 2011 | A1 |
20110087099 | Eshel et al. | Apr 2011 | A1 |
20110087255 | Mccormack et al. | Apr 2011 | A1 |
20110112405 | Barthe et al. | May 2011 | A1 |
20110178444 | Slayton et al. | Jul 2011 | A1 |
20110190745 | Uebelhoer et al. | Aug 2011 | A1 |
20110264012 | Lautzenhiser et al. | Oct 2011 | A1 |
20120004549 | Barthe et al. | Jan 2012 | A1 |
20120016239 | Barthe et al. | Jan 2012 | A1 |
20120029353 | Slayton et al. | Feb 2012 | A1 |
20120035475 | Barthe et al. | Feb 2012 | A1 |
20120035476 | Barthe et al. | Feb 2012 | A1 |
20120046547 | Barthe et al. | Feb 2012 | A1 |
20120053458 | Barthe et al. | Mar 2012 | A1 |
20120111339 | Barthe et al. | May 2012 | A1 |
20120143056 | Slayton et al. | Jun 2012 | A1 |
20120165668 | Slayton et al. | Jun 2012 | A1 |
20120165848 | Slayton et al. | Jun 2012 | A1 |
20120197120 | Makin et al. | Aug 2012 | A1 |
20120197121 | Slayton et al. | Aug 2012 | A1 |
20120215105 | Slayton et al. | Aug 2012 | A1 |
20120271294 | Barthe et al. | Oct 2012 | A1 |
20120296240 | Azhari et al. | Nov 2012 | A1 |
20120316426 | Foley et al. | Dec 2012 | A1 |
20120330197 | Makin et al. | Dec 2012 | A1 |
20120330222 | Barthe et al. | Dec 2012 | A1 |
20120330223 | Makin et al. | Dec 2012 | A1 |
20130012755 | Slayton | Jan 2013 | A1 |
20130012816 | Slayton et al. | Jan 2013 | A1 |
20130012838 | Jaeger et al. | Jan 2013 | A1 |
20130012842 | Barthe | Jan 2013 | A1 |
20130018286 | Slayton et al. | Jan 2013 | A1 |
20130310863 | Barthe et al. | Jan 2013 | A1 |
20130046209 | Slayton et al. | Feb 2013 | A1 |
20130066208 | Barthe et al. | Mar 2013 | A1 |
20130066237 | Smotrich et al. | Mar 2013 | A1 |
20130072826 | Slayton et al. | Mar 2013 | A1 |
20130096471 | Slayton et al. | Apr 2013 | A1 |
20130190659 | Slayton et al. | Jul 2013 | A1 |
20130211258 | Barthe et al. | Aug 2013 | A1 |
20130281853 | Slayton et al. | Oct 2013 | A1 |
20130281891 | Slayton et al. | Oct 2013 | A1 |
20130296697 | Slayton et al. | Nov 2013 | A1 |
20130296700 | Slayton et al. | Nov 2013 | A1 |
20130303904 | Barthe et al. | Nov 2013 | A1 |
20130303905 | Barthe et al. | Nov 2013 | A1 |
20140082907 | Barthe | Mar 2014 | A1 |
20140142430 | Slayton et al. | May 2014 | A1 |
20140148834 | Barthe et al. | May 2014 | A1 |
20140180174 | Slayton et al. | Jun 2014 | A1 |
20140187944 | Slayton et al. | Jul 2014 | A1 |
20140188015 | Slayton et al. | Jul 2014 | A1 |
20140188145 | Slayton et al. | Jul 2014 | A1 |
Number | Date | Country |
---|---|---|
4029175 | Mar 1992 | DE |
10140604 | Mar 2003 | DE |
10219217 | Nov 2003 | DE |
10219297 | Nov 2003 | DE |
20314479 | Mar 2004 | DE |
0344773 | Dec 1989 | EP |
1479412 | Nov 1991 | EP |
0473553 | Apr 1992 | EP |
0661029 | Jul 1995 | EP |
1050322 | Nov 2000 | EP |
1234566 | Aug 2002 | EP |
1262160 | Dec 2002 | EP |
1374944 | Jan 2004 | EP |
2113099 | Aug 1983 | GB |
63036171 | Feb 1988 | JP |
03048299 | Mar 1991 | JP |
3123559 | May 1991 | JP |
03136642 | Jun 1991 | JP |
4089058 | Mar 1992 | JP |
04150847 | May 1992 | JP |
7080087 | Mar 1995 | JP |
07505793 | Jun 1995 | JP |
7222782 | Aug 1995 | JP |
09047458 | Feb 1997 | JP |
11505440 | May 1999 | JP |
11506636 | Jun 1999 | JP |
2000166940 | Jun 2000 | JP |
2001170068 | Jun 2001 | JP |
2002078764 | Mar 2002 | JP |
2002515786 | May 2002 | JP |
2002521118 | Jul 2002 | JP |
2002537939 | Nov 2002 | JP |
2003050298 | Feb 2003 | JP |
2003204982 | Jul 2003 | JP |
2004147719 | May 2004 | JP |
2005503388 | Feb 2005 | JP |
2005527336 | Sep 2005 | JP |
2005323213 | Nov 2005 | JP |
2006520247 | Sep 2006 | JP |
2007505793 | Mar 2007 | JP |
2009518126 | May 2009 | JP |
2010517695 | May 2010 | JP |
1020010024871 | Mar 2001 | KR |
1020060113930 | Nov 2006 | KR |
1020070065332 | Jun 2007 | KR |
1020070070161 | Jul 2007 | KR |
1020070098856 | Oct 2007 | KR |
1020070104878 | Oct 2007 | KR |
1020070114105 | Nov 2007 | KR |
9625888 | Aug 1996 | WO |
9639079 | Dec 1996 | WO |
WO 9735518 | Oct 1997 | WO |
9832379 | Jul 1998 | WO |
WO 9933520 | Jul 1999 | WO |
WO 9949788 | Oct 1999 | WO |
0006032 | Feb 2000 | WO |
WO 0015300 | Mar 2000 | WO |
WO 0021612 | Apr 2000 | WO |
0053113 | Sep 2000 | WO |
WO 0128623 | Apr 2001 | WO |
WO 0182777 | Nov 2001 | WO |
WO 0182778 | Nov 2001 | WO |
WO 0187161 | Nov 2001 | WO |
0209813 | Feb 2002 | WO |
WO 0209813 | Feb 2002 | WO |
02024050 | Mar 2002 | WO |
WO 0224050 | Mar 2002 | WO |
WO 0292168 | Nov 2002 | WO |
03053266 | Jul 2003 | WO |
03065347 | Aug 2003 | WO |
WO 03070105 | Aug 2003 | WO |
WO 03077833 | Sep 2003 | WO |
03086215 | Oct 2003 | WO |
03096883 | Nov 2003 | WO |
03101530 | Dec 2003 | WO |
2004000116 | Dec 2003 | WO |
WO 03099177 | Dec 2003 | WO |
2004080147 | Sep 2004 | WO |
2004110558 | Dec 2004 | WO |
2005011804 | Feb 2005 | WO |
2005065408 | Jul 2005 | WO |
2005090978 | Sep 2005 | WO |
2006042163 | Apr 2006 | WO |
WO 2006042168 | Apr 2006 | WO |
WO 2006042201 | Apr 2006 | WO |
WO2006036870 | Apr 2006 | WO |
2006065671 | Jun 2006 | WO |
2006082573 | Aug 2006 | WO |
2007067563 | Jun 2007 | WO |
2008024923 | Feb 2008 | WO |
2008036622 | Mar 2008 | WO |
2009013729 | Jan 2009 | WO |
2009149390 | Dec 2009 | WO |
2014055708 | Apr 2014 | WO |
Entry |
---|
Non-Final Office Action mailed Feb. 12, 2007 in U.S. Appl. No. 10/944,500. |
Final Office Action mailed Oct. 3, 2008 in U.S. Appl. No. 10/944,500. |
Advisory Action mailed Mar. 4, 2009 in U.S. Appl. No. 10/944,500. |
Non-Final Office Action mailed Jul. 21, 2009 in U.S. Appl. No. 10/944,500. |
Notice of Allowance mailed Mar. 9, 2010 in U.S. Appl. No. 10/944,500. |
ISR and Written Opinion mailed Jan. 26, 2006 in Int'l Application No. PCT/US05/033195. |
IPRP mail Dec. 22, 2006 in Int'l Application No. PCT/US05/033195. |
Examination Report mailed Feb. 19, 2010 in European App. No. 08747803.8. |
Alster, Tinas S., Tanzi, Elizabeth L., “Cellulite Treatment using a Novel Combination Radiofrequency, Infrared Light, and Mechanical Tissue Manipulation Device,” Journal of Cosmetic & Laser Therapy, Jun. 2005, vol. 7, Issue 2, pp. 81-85. |
Barthe et al., “Ultrasound therapy system and abiation results utilizing miniature imaging/therapy arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1792-1795, vol. 3. |
Coon, Joshua et al., “Protein identification using sequential ion/ion reactions and tandem mass spectometry” Proceedings of the National Academy of Sciences of the USA, vol. 102, No. 27, Jul. 5, 2005, pp. 9463-9468. |
Corry, Peter M., et al., “Human Cancer Treatment with Ultrasound”, IEEE Transactions on Sonics and Ultrasonics, vol. SU-31, No. 5, Sep. 1984, pp. 444-456. |
Daum et al., “Design and Evaluation of a Feedback Based Phased Array System for Ultrasound Surgery,” IEEE Transactions on Ultrasonics, Feroelectronics, and Frequency Control, vol. 45, No. 2, Mar. 1998, pp. 431-438. |
Davis, Brian J., et al., “An Acoustic Phase Shift Technique for the Non-Invasive Measurement of Temperature Changes in Tissues”, 1985 Ultrasonics Symposium, pp. 921-924. |
Gliklich et al., Clinical Pilot Study of Intense Ultrasound therapy to Deep Dermal Facial Skin and Subcutaneous Tissues, Arch Facial Plastic Surgery, Mar. 1, 2007, vol. 9. |
Hassan et al., “Structure and Applications of Poly(vinyl alcohol) Hydrogels Produced by Conventional Crosslinking or by Freezing/Thawing Methods,” advanced in Polymer Science, 2000, pp. 37-65, vol. 153. |
Hassan et al., “Structure and Morphology of Freeze/Thawed PVA Hydrogels,” Macromolecules, Mar. 11, 2000, pp. 2472-2479, vol. 33, No. 7. |
Husseini et al, “The Role of Cavitation in Acoustically Activated Drug Delivery,” J. Control Release, Oct. 3, 2005, pp. 253-261, vol. 107(2). |
Husseini et al. “Investigating the mechanism of accoustically activated uptake of drugs from Pluronic micelles,” BMD Cancer 2002, 2:20k, Aug. 30, 2002, pp. 1-6. |
Jenne, J., et al., “Temperature Mapping for High Energy US-Therapy”, 1994 Ultrasonics Symposium, pp. 1879-1882. |
Johnson, S.A., et al., “Non-Intrusive Measurement of Microwave and Ultrasound-Induced Hyperthermia by Acoustic temperature Tomography”, Ultrasonics Symposium Proceedings, pp. 977-982. |
Makin et al, “B-Scan Imaging and Thermal Lesion Monitoring Using Miniaturized Dual-Functionality Ultrasound Arrays,” Ultrasonics Symposium, 2004 IEEE, Aug. 23, 2004, pp. 1788-1791, vol. 3. |
Makin et al, “Miniaturized Ultrasound Arrays for Interstitial Ablation and Imaging,” UltraSound Med. Biol. 2005, Nov. 1, 2005, pp. 1539-1550, vol. 31(11). |
Makin et al., “Confirmal Bulk Ablation and Therapy Monitoring Using Intracorporeal Image-Treat Ultrasound Arrays”, 4th International Symposium on Therapeutic Ultrasound, Sep. 19, 2004. |
Manohar et al, “Photoaccoustic mammography laboratory prototype: imaging of breast tissue phantoms,” Journal of Biomedical Optics, Nov./Dec. 2004, pp. 1172-1181, vol. 9, No. 6. |
Mast et al, “Bulk Ablation of Soft Tissue with Intense Ultrasound; Modeling nad Experiments,” J. Acoust. Soc. Am., Oct. 1, 2005, pp. 2715-2724, vol. 118(4). |
Paradossi et al., “Poly(vinyl alcohol) as versatile biomaterial for potential biomedical applications,” Journal of Materials Science: Materials in Medicine, 2003, pp. 687-691, vol. 14. |
Reid, Gavin, et al., “Tandem Mass spectrometry of ribonuclease A and B: N-linked glycosylation site analysis of whole protein ions,” Analytical Chemistry. Feb. 1, 2002, vol. 74, No. 3, pp. 577-583. |
Righetti et al, “Elastographic Characterization of HIFU-Induced Lesions in Canine Livers,” 1999, Ultrasound in Med & Bio, vol. 25, No. 7, pp. 1099-1113. |
Mitragotri, Samir; “Healing sound: the use of ultrasound in drug delivery and other therapeutic applications,” Nature Reviews; Drug Delivery, pp. 255-260, vol. 4. |
Sanghvi, N.T., et al., “Transrectal Ablation of Prostrate Tissue Using Focused Ultrasound,” 1993 Ultrasonics Symposium, IEEE, pp. 1207-1210. |
Seip, Ralf, et al., “Noninvasive Detection of Thermal Effects Due to Highly Focused Ultrasonic Fiels,” IEEE Symposium, pp. 1229-1232, vol. 2, Oct. 3-Nov. 1993. |
Seip, Ralf, et al., “Noninvasive Estimation of Tissue Temperature Response to Heating Fields Using Diagnostic Ultrasound,” IEEE Transactions on Biomedical Engineering, vol. 42, No. 8, Aug. 1995, pp. 828-839. |
Smith, Nadine Barrie, et al., “Non-Invasive In Vivo Temperature Mapping of Ultrasound Heating Using Magnetic Resonance Techniques”, 1994 Ultrasonics Symposium, pp. 1829-1832, vol. 3. |
Surry et al., “Poly(vinyl alcohol) cryogel phantoms for use in ultrasound and MR imaging,” Phys. Med. Biol., Dec. 6, 2004, pp. 5529-5546, vol. 49. |
Syka J. E. P. et al., “Peptide and Protein Sequence Analysis by Electron Transfer Dissociation Mass Spectometry,” Proceedings of the National Academy of Sciences of USA, National Academy of Aceince, Washington, DC, vol. 101, No. 26, Jun. 29, 2004, pp. 9528-9533. |
Ueno, S., et al., “Ultrasound Thermometry in Hyperthermia”, 1990 Ultrasonic Symposium, pp. 1645-1652. |
Wang, H., et al., “Limits on Focused Ultrasound for Deep Hyperthermia”, 1994 Ultrasonic Symposium, Nov. 1-4, 1994, pp. 1869-1872, vol. 3. |
White et al “Selective Creation of Thermal Injury Zones in the Superficial Musculoaponeurotic System Using Intense Ultrasound Therapy,” Arch Facial Plastic Surgery, Jan./Feb. 2007, vol. 9, No. 1. |
Sassen, Sander, “ATI's R520 architecture, the new king of the hill?” http://www.hardwareanalysis.com/content/article/1813, Sep. 16, 2005, 2 pages. |
Wasson, Scott, “NVIDIA's GeFroce 7800 GTX graphics processor Power MADD,” http://techreport.com/reviews/2005q2/geforce-7800gtx/index.x?pg=1, Jun. 22, 2005, 4 pages. |
Notification of Transmittal of the International Search Report and the Written Opinion of the International Searching Authority, or the Declaration from PCT/US2008-062936 mailed Sep. 25, 2008. |
International Preliminary Report on Patentability for International application No. PCT/US2008/062936 dated Nov. 19, 2009. |
Chen, L. et al., ““Effect of Blood Perfusion on the ablation of liver perenchyma with high intensity focused ultrasound,”” Phys. Med. Biol; 38:1661-1673; 1993b. |
Damianou et al., Application of the Thermal Dose Concept for Predicting the Necrosed Tissue Volume During Ultrasound Surgery, 1993 IEEE Ultrasound Symposium, pp. 1199-1202. |
Fry, W.J. et al., “Production of Focal Destructive Lesions in the Central Nervous System with Ultrasound,” J. Neurosurg., 11:471-478; 1954. |
Harr, G.R. et al., “Tissue Destruction with Focused Ultrasound in Vivo,” Eur. Urol. 23 (suppl. 1):8-11; 1993. |
Jeffers et al., “Evaluation of the Effect of Cavitation Activity on Drug-Ultrasound Synergisms,” 1993 IEEE Ultrasonics Symposium, pp. 925-928. |
Madersbacher, S. et al., “Tissue Ablation in Bening Prostatic Hyperplasia with High Intensity Focused Ultrasound,” Dur. Urol., 23 (suppl. 1):39-43; 1993. |
Saad et al., “Ultrasound-Enhanced Effects of Adriamycin Against Murine Tumors,” Ultrasound in Med. & Biol. vol. 18, No. 8, pp. 715-723 (1992). |
Simon et al., “Applications of Lipid-Coated Microbubble Ultrasonic Contrast to Tumor Therapy,” Ultrasound in Med. & Biol. vol. 19, No. 2, pp. 123-125 (1993). |
Talbert, D. G., “An Add-On Modification for Linear Array Real-Time Ultrasound Scanners to Produce 3D Displays,” UTS Int'l 1977 Brighton, England (Jun. 28-30, 1977) pp. 57-67. |
Tata et al., “Interaction of Ultrasound and Model Membrane Systems: Analyses and Predictions,” American Chemical Society, Phys. Chem. 1992, 96, pp. 3548-3555. |
European Examination Report in related Application No. 05808908.7 dated Jun. 29, 2009. |
European Examination Report in related Application No. 05810308.6 dated Jun. 29, 2009. |
European Examination Report in related Application No. 10185100.4 dated Jan. 6, 2014. |
European Examination Report in related Application No. 10185120.2 dated Jan. 22, 2014. |
Decision of the Korean Intellectual Property Tribunal dated Jun. 28, 2013 regarding Korean Patent No. 10-1142108, which is related to the pending application and/or an application identified in the Table on the pp. 2-5 of the information Disclosure Statement herein (English translation, English translation certification, and Korean decision included). |
International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046122. |
International Search Report and Written Opinion dated Jan. 23, 2014 in Application No. PCT/US2012/046123. |
International Search Report and Written Opinion dated Jan. 28, 2012 in Application No. PCT/US2012/046327. |
International Search Report and Written Opinion dated Jan. 28, 2013 in Application No. PCT/US2012/046125. |
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001361. |
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001362. |
International Search Report and Written Opinion dated Feb. 14, 2013 in Application No. PCT/US2011/001366. |
International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001367. |
Arthur et al., “Non-invasive estimation of hyperthermia temperatures with ultrasound,” Int. J. Hyperthermia, Sep. 2005, 21(6), pp. 589-600. |
International Search Report and Written Opinion dated Mar. 28, 2012 in Application No. PCT/US2011/001362. |
Calderhead et al., One Mechanism Behind LED Photo-Therapy for Wound Healing and Skin Rejuvenation: Key Role of the Mast Cell, Laser Therapy, Jul. 2008, pp. 141-148, 17.3. |
European Examination Report in related Application No. 09835856.7 dated Apr. 11, 2004. |
International Search Report and Written Opinion dated Apr. 6, 2012 in Application No. PCT/US2011/001366. |
PCT International Search Report and Written Opinion, PCT/US2014/030779, Sep. 1, 2014, 8 pages. |
European Patent Office, Examination Report, EP 07814933.3, Aug. 5, 2014, 5 pages. |
European Patent Office, Examination Report, EP 05798870.1, Oct. 20, 2014, 5 pages. |
European Patent Office, Examination Report, EP 10185100.4, Oct. 24, 2014, 4 pages. |
European Patent Office, Examination Report, EP 10185112.9, Oct. 24, 2014, 5 pages. |
European Patent Office, Examination Report, EP 10185117.8, Oct. 24, 2014, 5 pages. |
European Patent Office, Examination Report, EP 10185120.2, Oct. 24, 2014, 4 pages. |
Number | Date | Country | |
---|---|---|---|
20080221491 A1 | Sep 2008 | US |
Number | Date | Country | |
---|---|---|---|
60916475 | May 2007 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10944500 | Sep 2004 | US |
Child | 12116845 | US |